These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...

Ocean Biomedical (OCEA) announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy ...

Company Poised to Enter Booming Bispecific Antibody Market Amid Growing Pharma Interest Providence, RI, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Ocean Biomedical (NASDAQ: OCEA) today announced newly ...

("BioRay") announced thatNMPA) has accepted the clinical trial application for its self-developed Class 1 innovative therapeutic biological product, BR111 for injection. BR111 is an antibody-drug ...

Tagrisso was linked to higher cardiac risks in patients with EGFR-mutant NSCLC, including a four-fold rise in cardiac events ...

L-tyrosine is taking off as “liquid Adderall” within the ADHD community on TikTok. Some social media creators are touting it as a “natural” alternative to prescription medications, while others prefer ...

DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for c-MET-NSCLC treatment. The leading c-MET-NSCLC Companies such as ...

Sevenless, the Drosophila homologue of ROS1 (dROS1) is a receptor tyrosine kinase essential for the differentiation of photoreceptor cells and activated by binding to the GPCR Bride Of Sevenless ...

A Chinese study, led by Arnold ASH Chee, AFCOphthHK, found that a tyrosine kinase inhibitor achieved both durable disease control and visual improvement in patients with epidermal growth factor ...

Department of Biomedical Engineering, University of West Attica, Ag. Spyridonos, Egaleo 12243, Greece ...